How strict are you about adhering to the eligibility criteria required for entry onto the OlympiA trial in considering a year of adjuvant olaparib as adjuvant therapy for BRCA mutated, node positive, ER positive breast cancer?  

If a patient had a CPS-EG of 2 after neoadjuvant therapy, would you offer that patient olaparib even though she wouldn't have met entry criteria? If this patient met criteria for adjuvant abemaciclib would you offer that instead?

Answer from: Medical Oncologist at Academic Institution
Medical Oncologist at Alvin & Lois Lapidus Cancer Institute Northwest Hospital
If you could get coverage for olaparib inpatients ...
Sign in or Register to read more